Greek Govt Adjusts Prices Of 6,009 Drugs

2 October 1997

In an attempt to cut health care costs by 80 billion drachmas ($287.2million) a year, the Greek government has announced price reductions averaging 19% on 4,075 drugs and a 14% increase on the prices of 1,934 drugs.

Deputy Development Minister Michalis Chrysochoidis said the largest price reductions, which are as much as 85% in some cases) involve very expensive drugs, the majority of which are produced abroad, and whose Greek prices are considerably higher than in the "cheapest" European countries. The increases involve widely-used drugs, mainly produced in Greece.

The government is also tightening social security drug spending. A list of government-approved drugs will shortly be issued for social security funds and state hospitals. To reinforce the accompanying guidelines on cost-effective prescribing, the Greek Pharmaceutical Organization will publish a new list of drugs, to include all the main components of each product. Some of the main price changes follow:

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight